In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and Monitoring...

In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and
Monitoring of Leukemia
During the Last Quarter of 2008, Ipsogen Launched Three New Molecular
Diagnostic Kits

MARSEILLE, France, January 12 /PRNewswire-FirstCall/ -- IPSOGEN SA
(Alternext - FR0010626028 - ALIPS), a cancer profiler that develops and
markets molecular diagnostic products for leukemia and breast cancer has
launched 3 new products during the fourth quarter of 2008, that expand its
leukemia molecular diagnostic portfolio:
- FusionQuant BCR-ABL IVD kit, used in the the detection and monitoring
of chronic myeloid leukemias (CML), is a new CE marked expanded
version of our existing product. The new IVD kit now provides all the
necessary components in one package adding convenience and efficiency
in the lab. The improved kit will also support the much needed test
standardisation required for proper disease monitoring

- ProfileQuant CLLU1, in chronic lymphocytic leukemia (CLL).
This research kit provides prognostic information, and has the
potential to play a significant role in the monitoring of this disease.

- MutaScreen MPL, a research kit for the detection of MPL mutations in
JAK2 negative myeloproliferative neoplams (MPN), is a significant
addition to the MPD family of products that Ipsogen offers.

These 3 new tests exemplify Ipsogen's strategy of (i) introducing
technological and scientific innovation to address unmet diagnostic needs,
and (ii) rapidly translating scientific discoveries into patient bedside
tools, in line with the ultimate objective of enabling better and more
personalised disease management.
"In the last quarter of 2008, we launched 3 new products. With 21 kits
now in distribution, of which 10 are CE marked, Ipsogen's molecular
diagnostic portfolio covers a significant range of the leukemia spectrum.
These new products will help hematologists refine and improve treatment
strategies" says Stephane Debono, COO and in charge of product planning..
Vincent Fert, CEO, concludes: 'These 3 new product launches are in line
with our 2008 plans, and will further equip our sales staff with a
comprehensive and market leading range of leukemia products that helps
consolidate our leadership position in this growing market'.
Next Press Release announcement - Full-year Sales 2008: 18 February 2009
(after market)
About IPSOGEN
Ipsogen, Cancer Profiler, develops and markets molecular diagnostic tests
designed to map diseases in order to guide patients and oncologists decisions
along their complex therapeutic path.
With more than 70 tests already used routinely worldwide for the
diagnosis, prognosis and follow-up of thousands of patients with leukemia,
Ipsogen is now also targeting breast cancer. Its initial goal will be to
provide diagnostic information that remained unavailable until now.
Strengthened by its first-rate scientific, clinical and technological
partnerships, in addition to its highly skilled multidisciplinary team in
France and the USA, Ipsogen is striving to become the leader in the molecular
profiling of cancers. It is pursuing its development and promotion of
diagnostic standards that have a significant impact on patients, medical
professionals and society.
Ipsogen employed 48 people as of December 31, 2008. Its headquarters are
located in Marseilles, France. The company has also a subsidiary, Ipsogen
Inc., in New Haven, CT, USA.
For more information, visit: http://www.ipsogen.com
SOURCE Ipsogen SA

Contacts: IPSOGEN Vincent Fert, President and CEO, Tel.: +33(0)4-9129-3090;
fert@ipsogen.com; Stanislas Piot, CFO, Tel.: +33(0)4-9129-3090,
piot@ipsogen.com; ATCG Press, Corporate and Product, Information, Marielle
Bricman, Tel.: +33(0)4-9125-0785, ipsogen@atcg-partners.com; NewCap, Financial
Communication and Investor Relations, Axelle Vuillermet & Pierre, Laurent,
Tel.: +33(0)1-44-71-94-93, ipsogen@newcap.fr